pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ATG-201, the most common co-covered peer. At 6, the average consequence score sits below the same-window beat average of 6.4.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Antengene
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ATG-201, the most common co-covered peer. At 6, the average consequence score sits below the same-window beat average of 6.4. They are better corroborated than the beat average, carrying 3 original sources each against 2.8 for the same window. Antengene appears in 1 tracked Biotech story from March 20, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Antengene. Shared-story counts are live from our verified record — not editorial picks.
Antengene Corporation has reported its 2025 full-year financial results, highlighted by the first successful out-licensing of its proprietary T-cell engager (TCE) platform. This strategic milestone validates the company's R&D capabilities and establishes a clear path toward projected profitability by 2026.
Antengene is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.